Rejuvenate Biomed

Executive Summary

Rejuvenate Biomed is a Belgian clinical-stage biotechnology company founded in 2016, dedicated to discovering and developing therapeutics that promote healthy aging and combat multiple age-related diseases. Leveraging an AI-enabled platform for drug repurposing and development, the company focuses on RNA & Gene Therapy and Small Molecules. Its lead program targets COPD-related muscle weakness and sarcopenia, conditions with significant unmet need in the aging population. Rejuvenate Biomed is currently in Phase 2 clinical development, positioning itself to address the multifactorial aspects of aging through a portfolio of repurposed and novel compounds.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 data readout for lead program in sarcopenia and COPD muscle weakness60% success
• Q2 2026New AI platform partnership or licensing deal to expand pipeline40% success
• Q3 2026Series A or B financing round to advance clinical trials70% success